

## The Hydrolysis Products of *cis*-Dichlorodiammineplatinum(II)

### 3. Hydrolysis Kinetics at Physiological pH

SIAN E. MILLER and DONALD A. HOUSE\*

Department of Chemistry, University of Canterbury, Christchurch (New Zealand)

(Received November 21, 1989)

#### Abstract




The rate of hydrolysis of *cis*-PtCl<sub>2</sub>(NH<sub>3</sub>)<sub>2</sub> has been measured in non-buffered aqueous solution (*I* = 0.2 M NaClO<sub>4</sub>; *T* = 45.0 °C) at constant pH over the range pH = 4.0–8.5 using a combined pH-stat/spectrophotometric technique. The hydrolysis rate at pH = 7.4 (*T* = 45.0 °C) was also determined with [Cl<sup>-</sup>] = 0.0–0.1 M (*I* = 0.2 M; NaCl, NaClO<sub>4</sub>). At the end of each kinetic run, the resulting solution was made 0.2 M in Cl<sup>-</sup> by the addition of NaCl and the reverse (anation) reaction was monitored, again under constant pH conditions. A knowledge of the complete pH-rate profile, with and without added chloride ion, allows current models for the hydrolysis of *cis*-PtCl<sub>2</sub>(NH<sub>3</sub>)<sub>2</sub> under physiological conditions, to be tested. *cis*-Pt(NH<sub>3</sub>)<sub>2</sub>(OH<sub>2</sub>)<sub>2</sub><sup>2+</sup> is considered to be the least important of all the potential hydrolysis products available to bind to replicating DNA at pH = 7.4.

#### Introduction

*cis*-PtCl<sub>2</sub>(NH<sub>3</sub>)<sub>2</sub> is used extensively in antitumor cancer therapy [1]. We have previously measured the hydrolysis kinetics of *cis*-PtCl<sub>2</sub>(NH<sub>3</sub>)<sub>2</sub> in both acidic [2] and basic [3] solution. Table 1 summarises the characteristic features, the most important being that in acid solution an equilibrium is established

\*Author to whom correspondence should be addressed.

(eqn. (1)), but in basic solution, irreversible hydrolysis occurs (eqn. (3)) and both chloro ligands are lost.



In acid solution, reaction (1) does not proceed further (eqn. (2)) to produce significant amounts of *cis*-Pt(NH<sub>3</sub>)<sub>2</sub>(OH<sub>2</sub>)<sub>2</sub><sup>2+</sup>, as the small value for the equilibrium constant associated with eqn. (2) (*K*<sub>2</sub> = 2.7 × 10<sup>-4</sup> at 25 °C [3]) effectively prevents further chloride ion release. The forward rate constants for eqns. (1), (2) and (3) are in the ratio of 1.00:0.37:0.20 respectively [2, 3] (see Scheme 1).

A second important feature is that the extent of acid hydrolysis, according to eqns. (1) and (2), is chloride ion dependent, whereas if hydrolysis takes place according to eqn. (3), the reaction proceeds to completion independent of the chloride ion concentration [3].

TABLE 1. Comparison of hydrolysis data for *cis*-PtCl<sub>2</sub>(NH<sub>3</sub>)<sub>2</sub> in acidic and basic solution [2, 3]

	Kinetic parameters 25 °C ( <i>μ</i> = 0.1 M)	Final products	Comments
Acid (0.1 M HClO <sub>4</sub> )	<i>k</i> <sub>1</sub> = 7.56 × 10 <sup>-5</sup> s <sup>-1</sup> Δ <i>H</i> <sup>‡</sup> = 73.7 kJ mol <sup>-1</sup> Δ <i>S</i> <sup>‡</sup> = -76.5 J K <sup>-1</sup> mol <sup>-1</sup>	Equilibrium mixture of <i>cis</i> -PtCl <sub>2</sub> (NH <sub>3</sub> ) <sub>2</sub> , <i>cis</i> -PtCl(NH <sub>3</sub> ) <sub>2</sub> (OH <sub>2</sub> ) <sub>2</sub> <sup>+</sup> and Cl <sup>-</sup>	Rate independent of [H <sup>+</sup> ] and ionic strength; extent of reaction Suppressed by added Cl <sup>-</sup>
Base (0.1 M NaOH)	<i>k</i> <sub>3</sub> = 1.90 × 10 <sup>-5</sup> s <sup>-1</sup> Δ <i>H</i> <sup>‡</sup> = 84.4 kJ mol <sup>-1</sup> Δ <i>S</i> <sup>‡</sup> = -52 J K <sup>-1</sup> mol <sup>-1</sup>	<i>cis</i> -Pt(OH) <sub>2</sub> (NH <sub>3</sub> ) <sub>2</sub> and 2 Cl <sup>-</sup>	Rate independent of [OH <sup>-</sup> ], ionic strength and [Cl <sup>-</sup> ]

It is thus important to determine the pH-rate profile in the range pH = 4–9, and this is the basis of the present publication.

## Experimental

*cis*-PtCl<sub>2</sub>(NH<sub>3</sub>)<sub>2</sub> was purchased from Strem Chemical Company and used as supplied. All other reagents were AR quality or the best reagent grade available. A Radiometer pH-stat (TTTlc) coupled to a Radiometer Titrigraph (SBR2) with the appropriate glass (G202C) and calomel (TS-1) electrodes was used for all pH measurements. The instrument was calibrated with 0.01 M borax buffer (pH = 9.038 at 45.0 °C). A Varian DMS100 recording spectrophotometer was used to record the UV (345–220 nm) spectra of the reacting solutions.

### Kinetic Measurements at Constant pH

A total of 50 mg of *cis*-PtCl<sub>2</sub>(NH<sub>3</sub>)<sub>2</sub> was dissolved in c. 5 ml of DMF, and this solution was added to 70 ml of 0.2 M NaClO<sub>4</sub> solution (NaClO<sub>4</sub>; NaCl, *I* = 0.2 M when Cl<sup>-</sup> variation studies were performed) in the temperature controlled (45.0 ± 0.1 °C) reaction vessel of the Radiometer pH-stat while this solution was being peristaltically pumped (100 ml/min) through a 2.00 cm flow-through cell in the Varian spectrophotometer. Glass and calomel electrodes were placed in the reactant solution and the pH adjusted to just above the set pH by the addition of dilute acid or alkali. As the hydrolysis proceeds (above pH = 5), the pH drops and when the set pH was reached, the pH-stat system was activated by the automatic addition of NaOH solution (0.05 M) through a stainless steel needle. When constant pH

was satisfactorily maintained, the repeat scan/fixed wavelength modes of the spectrophotometer were activated to monitor absorbance with time. The concentrations are such that 6.66 ml of 0.05 M NaOH is required if two moles of OH<sup>-</sup> are used per mole of platinum(II). Thus, the proportion of NaOH for complete reaction, the rate of NaOH uptake and the rate of spectrophotometric change were measured simultaneously.

Control experiments showed the system behaved identically if the DMF was not present.

On the completion of each kinetic run, NaCl (0.877 g) was added to the reaction solution to give a [Cl<sup>-</sup>] of 0.2 M and the repeat scan mode of the spectrophotometer was reactivated. Constant pH was maintained by periodic manual addition of 0.1 M HClO<sub>4</sub>. Under these conditions, aqua ligands coordinated to Pt(II) are fairly rapidly replaced by Cl<sup>-</sup>. The results are summarised in Table 2.

## Results and Discussion

The generally accepted mechanism for the interaction of *cis*-PtCl<sub>2</sub>(NH<sub>3</sub>)<sub>2</sub> with the target DNA molecule is as follows [4]. *cis*-PtCl<sub>2</sub>(NH<sub>3</sub>)<sub>2</sub>, stabilised in saline solution, enters the blood stream under high hydration therapy [5]. The relatively high chloride ion concentration (~100 mM) in blood plasma prevents hydrolysis of the chloro ligands and the neutral molecule passes through the cell wall. Once inside the cell, hydrolysis according to eqn. (1) can now proceed as the background chloride ion concentration has dropped to ~4 mM. The positively charged (chloro)(aqua) product is the most likely labile complex for donor groups in the DNA target,

TABLE 2. Rate data for the hydrolysis of *cis*-PtCl<sub>2</sub>(NH<sub>3</sub>)<sub>2</sub> at various fixed pH in unbuffered media (*I* = 0.2 M, NaClO<sub>4</sub>; *T* = 45.0 °C)

Set pH	OH <sup>-</sup> uptake (mole/mole Pt(II))	10 <sup>4</sup> × <i>k</i> <sub>obs</sub> <sup>a</sup> (s <sup>-1</sup> )	Isosbestic points (nm)	Chloride ion uptake <sup>b</sup> 10 <sup>4</sup> × <i>k</i> <sub>Cl</sub> (s <sup>-1</sup> )	Isosbestic points <sup>c</sup> (nm)
2.0	0.00	3.80 ± 0.35	282	d	d
4.0	0.00	3.71 ± 0.25	283	83.5 ± 4	d
5.5	0.00	3.57 ± 0.44	277 then 289	68.2 ± 6	281 then 289
6.0	0.37	3.37 ± 0.33	277 then 285	45.5 ± 3	277 then 287
6.5	0.68	3.13 ± 0.17	274 then 284	15.9 ± 2	274 then 284
6.8	0.62	2.50 ± 0.19	272 then 280	12.9 ± 0.6	273 then 285
7.0	0.77	2.37 ± 0.11	271 then 279	10.9 ± 0.7	272 then 285
7.2	0.90	2.04 ± 0.25	277	9.43 ± 0.5	273
7.5	1.10	1.97 ± 0.15	276	7.67 ± 0.4	271
8.0	1.28	1.79 ± 0.16	276	5.48 ± 0.4	270
8.5	1.71	1.87 ± 0.25	276	4.06 ± 0.4	273
12.0	2.0	1.84	276	no reaction	


<sup>a</sup>Observed first order rate constant for the overall forward reaction. <sup>b</sup>Final [Cl<sup>-</sup>] = 0.2 M. *k*<sub>Cl</sub> is proportional to the total *cis*-PtX(NH<sub>3</sub>)<sub>2</sub>(OH<sub>2</sub>)<sup>+</sup> concentration [X = Cl, OH]. <sup>c</sup>For the chloride ion anation reaction. <sup>d</sup>The reaction was too fast to obtain these accurately.





depend on the  $K_a$  for the (chloro)(aqua)–(chloro)–(hydroxo) equilibrium ( $pK_a = 6.85$  at  $4^\circ\text{C}$  [51]) and the set pH. The position of the isosbestic point will also depend on the value of the ratio.  $cis\text{-PtCl}(\text{NH}_3)_2(\text{OH}_2)^+$  will not hydrolyse spontaneously due to an unfavourable chloride ion dependent equilibrium [3], but  $cis\text{-PtCl}(\text{OH})(\text{NH}_3)_2$  can hydrolyse (at a rate about  $5 \times$  slower than the first hydrolysis step [3]) independent of the chloride ion concentration. Reduction of the  $cis\text{-PtCl}(\text{OH})(\text{NH}_3)_2$  concentration (by hydrolysis to  $cis\text{-Pt}(\text{OH})(\text{NH}_3)_2(\text{OH}_2)^+$ ) will result in a reduction of the  $cis\text{-PtCl}(\text{NH}_3)_2(\text{OH}_2)^+$  concentration as the equilibrium ratio must be maintained at a value determined by the set pH. Eventually the released chloride ion will establish an equilibrium with the  $cis\text{-Pt}(\text{OH})(\text{NH}_3)_2(\text{OH}_2)^+$  and further chloride ion release from  $cis\text{-PtCl}(\text{OH})(\text{NH}_3)_2$  will stop, but it is this second step that maintains the second isosbestic point. The final solution contains a mixture of  $cis\text{-PtCl}(\text{NH}_3)_2(\text{OH}_2)^+$ ,  $cis\text{-PtCl}(\text{OH})(\text{NH}_3)_2$ ,  $cis\text{-Pt}(\text{OH})(\text{NH}_3)_2(\text{OH}_2)^+$  and  $\text{Cl}^-$  ion, with the concentration of the former becoming smaller as the set pH is increased. Addition of chloride ion to this mixture results in the anation of the  $\text{Pt}-\text{OH}_2^{n+}$  species, reversing the hydrolysis steps and producing a final mixture of  $cis\text{-PtCl}_2(\text{NH}_3)_2$  and  $cis\text{-PtCl}(\text{OH})(\text{NH}_3)_2$ .


As the set pH is further increased (7.2–8.5), the (hydroxo)(aqua)–di(hydroxo) equilibrium becomes dominant ( $pK_a = 7.87$  at  $25^\circ\text{C}$  [51]) and the reaction rate slows.



Scheme 1.  $T = 45.0^\circ\text{C}$ , data from refs. 2, 3, 51.

In this region, the rate is controlled by chloride release from the (chloro)(hydroxo) [the slowest step] to give an equilibrium mixture of (chloro)–(hydroxo), (hydroxo)(aqua) and di(hydroxo) with the proportion of di(hydroxo) increasing with increasing set pH. Addition of chloride ion again results in anation of all  $\text{Pt}-\text{OH}_2^{n+}$  species and as these are dominated by  $cis\text{-Pt}(\text{OH})(\text{NH}_3)_2(\text{OH}_2)^+$ , the final anated mixture consists of  $cis\text{-PtCl}(\text{OH})(\text{NH}_3)_2$  and  $cis\text{-Pt}(\text{OH})_2(\text{NH}_3)_2$ . As the fixed pH is increased, the amount of  $cis\text{-Pt}(\text{OH})(\text{NH}_3)_2(\text{OH}_2)^+$  in the final mixture decreases and the extent of chloride ion uptake also decreases.

A summary of the hydrolysis processes in the absence of added chloride ion is shown in Scheme 1 and the system would be complete if rate ( $k_r$ ) and equilibrium constants ( $K_{\text{eq}} = k_f/k_r$ ) were known for reaction (7).



We are currently exploring techniques to make such measurements, with due cognisance of the possibility of competitive dimerisation of the (hydroxo)–(aqua).

A series of kinetic runs were performed at  $\text{pH} = 7.4$ ,  $T = 45.0^\circ\text{C}$ ,  $[\text{Pt}(\text{II})]_t = 2.2 \times 10^{-3} \text{ M}$  with varying amounts of  $\text{Cl}^-$  present ( $I = 0.2 \text{ M}$ ;  $\text{NaCl}$ ,  $\text{NaClO}_4$ ) (Table 3). At  $[\text{Cl}^-] = 0$ , and  $\text{pH} = 7.4$  the

TABLE 3. Rate data for the hydrolysis of *cis*-PtCl<sub>2</sub>(NH<sub>3</sub>)<sub>2</sub> at pH = 7.4 with variable chloride ion concentration (*I* = 0.2 M, NaClO<sub>4</sub>, NaCl; *T* = 45 °C, [*cis*-PtCl<sub>2</sub>(NH<sub>3</sub>)<sub>2</sub>] = 2.2 mM)

[Cl <sup>-</sup> ] <sub>i</sub> (M)	OH <sup>-</sup> uptake (mole/mole Pt(II))		10 <sup>4</sup> × <i>k</i> <sub>obs</sub> <sup>a</sup> (s <sup>-1</sup> )		Cl <sup>-</sup> uptake <sup>b</sup> 10 <sup>4</sup> × <i>k</i> <sub>Cl</sub> (s <sup>-1</sup> )	
	obs.	calc. <sup>c</sup>	obs.	calc. <sup>d</sup>	obs.	calc. <sup>e</sup>
0.00	1.08	1.08	1.97 ± 0.15	1.97	7.95 ± 0.4	7.95
0.010	0.68	1.00	2.12 ± 0.10	2.15	7.47 ± 0.4	7.65
0.025	0.71	0.90	2.48 ± 0.12	2.43	6.16 ± 0.4	7.20
0.050	0.75	0.72	2.61 ± 0.19	2.90	7.04 ± 1	6.44
0.075	0.38	0.53	3.32 ± 0.59	3.34	5.86 ± 1	5.68
0.100	0.35	0.35	4.23 ± 0.88	3.80	4.93 ± 0.3	4.93

<sup>a</sup>First order rate constant for the overall forward reaction. <sup>b</sup>Final [Cl<sup>-</sup>] = 0.2 M. The rate is proportional to the amount of *cis*-PtCl(NH<sub>3</sub>)<sub>2</sub>(OH<sub>2</sub>)<sup>+</sup> at equilibrium after completion of the forward reaction. <sup>c</sup>Calculated from the linear relationship: mole OH<sup>-</sup> uptake/mole Pt(II) = 1.08 - 7.3 [Cl<sup>-</sup>]<sub>i</sub> (*T* = 45.0 °C, pH = 7.4, *I* = 0.2 M). <sup>d</sup>Calculated from the linear relationship: 10<sup>4</sup> × *k*<sub>obs</sub> = 18.3 [Cl<sup>-</sup>]<sub>i</sub> + 1.97 (45.0 °C, pH = 7.4, *I* = 0.2 M). <sup>e</sup>Calculated from the linear relationship: 10<sup>4</sup> × *k*<sub>Cl</sub> = 7.95 - 30.2 [Cl<sup>-</sup>]<sub>i</sub> (45.0 °C, pH = 7.4, [Cl<sup>-</sup>] = 0.2 M, *I* = 0.2 - 0.3).

hydrolysis reaction is monophasic (see earlier), an equilibrium mixture of (chloro)(hydroxo) and (hydroxo)(aqua) is produced in about a 60:40 ratio (*pK*<sub>a</sub> for the (chloro)(aqua)-(chloro)(hydroxo) = 6.85 [51]), and 1 mol of OH<sup>-</sup> is consumed/mole of Pt(II). The increase in *k*<sub>obs</sub> with increasing [Cl<sup>-</sup>] is due to the fact that the system is proceeding to equilibrium and simple first order kinetics are not strictly applicable to eqn. (1). As the [Cl<sup>-</sup>] increases the amount of OH<sup>-</sup> uptake decreases, the extent of the reaction decreases, but the ratio of (chloro)(aqua) to (chloro)(hydroxo) remains constant as the pH is constant. Naturally, the rate of reverse reaction (with excess Cl<sup>-</sup>) decreases with increasing initial [Cl<sup>-</sup>] because the amount of (chloro)(aqua) at equilibrium is decreasing. At [Cl<sup>-</sup>]<sub>initial</sub> of 0.1 M, the final equilibrium ratio of products (pH = 7.4, *T* = 45.0 °C) is about 50% di(chloro), 30% (chloro)(hydroxo) and 20% (chloro)(aqua). This result is obtained from the self consistency of the following features:

(a) the final visible absorption spectra of the hydrolysis reaction

(b) the uptake of 0.37 mol of OH<sup>-</sup> per mole of Pt(II)

(c) the rate of chloride anation

(d) the final visible absorption spectra of the anation reaction

(e) the *pK*<sub>a</sub> value of 6.85 [51] for the (chloro)(aqua)-(chloro)(hydroxo) equilibrium. We estimate that this equilibrium mixture would be produced in about 6 h at 37 °C under the above conditions of pH and [Cl<sup>-</sup>]<sub>i</sub> and as the [Pt(II)]<sub>initial</sub> drops, the proportion of dichloro still present at equilibrium will increase.


Hydrolysis schemes for the reaction of *cis*-PtCl<sub>2</sub>(NH<sub>3</sub>)<sub>2</sub> in the biological milieu are frequently re-

ported [52-58] but the relative importance of any particular species is not normally highlighted.

One of the most successful attempts is that of LeRoy *et al.* [53] who analyse their hydrolysis scheme in terms of the equilibrium constant data known at that time (1979). They conclude that at pH = 7.5 and *T* = 37 °C with [Cl<sup>-</sup>] = 0.1 M and [Pt]<sub>t</sub> = 10<sup>-6</sup> M the dichloro (>83%), (chloro)(aqua) (4%) and (hydroxo)(aqua) (12%) species predominate and that the di(hydroxo), di(aqua) and (hydroxo)(aqua) species are present at the <1% level. Using more modern estimates for the equilibrium constants [2, 3, 51] we calculate 68%, 7% and 24% for the above, most predominate species, respectively, at pH = 7.5, [Cl<sup>-</sup>] = 0.1 M, [Pt]<sub>t</sub> = 10<sup>-3</sup> M and *T* = 25 °C.

In cytoplasm, the [Cl<sup>-</sup>] drops to ~4 mM and LeRoy *et al.* [53] calculate 31% dichloro, 28% (chloro)(aqua), 32% (hydroxo)(chloro), and 7% (hydroxo)(aqua) with the di(hydroxo) and di(aqua) at the <1% level. Although quite different conclusions are reached by Roos [54] (47% di(aqua) in cytoplasm medium), we agree with the analysis of LeRoy *et al.* and suggest that *cis*-Pt(NH<sub>3</sub>)<sub>2</sub>(OH<sub>2</sub>)<sub>2</sub><sup>2+</sup> is one of the least likely Pt(II) species, at physiological pH, for attack by donor atoms on DNA. Consequently, while studies using *cis*-Pt(NH<sub>3</sub>)<sub>2</sub>(OH<sub>2</sub>)<sub>2</sub><sup>2+</sup> plus nucleophiles as models for the *cis*-DDP/DNA interaction may provide an order of nucleophilic ability, they probably have little relevance to processes taking place at the site of the replicating cancer cells.

Our observations that buffer nucleophiles interact readily with *cis*-PtCl<sub>2</sub>(NH<sub>3</sub>)<sub>2</sub> hydrolysis products make the models for Pt(II) transport in biological systems (such as blood plasma) extremely difficult to design.



Scheme 2.  $\text{NH}_3$  ligands have been omitted.

If  $\text{cis-PtCl}_2(\text{NH}_3)_2$  were to hydrolyse in the blood stream at  $\text{pH} = 7.4$  via eqns. (5) and (6), then blood serum albumin or other plasma protein would be the most likely nucleophiles for the  $\text{cis-Pt}(\text{X})(\text{NH}_3)_2(\text{OH}_2)^+$  ( $\text{X} = \text{OH}, \text{Cl}$ ) species. This is equivalent to the buffer nucleophile situation. If the anating ligands are neutral, the resulting complex will remain charged and be effectively wasted, as transport of charged species across cell membranes is less likely than transport of neutral complexes. The most likely neutral species are the unreacted parent,  $\text{cis-PtCl}_2(\text{NH}_3)_2$ , and  $\text{cis-Pt}(\text{OH})(\text{Cl})(\text{NH}_3)_2$  although there could also be traces of  $\text{cis-Pt}(\text{OH})_2(\text{NH}_3)_2$ . A somewhat speculative model is given in Scheme 2.

## Conclusions

Our results for the hydrolysis of  $\text{cis-PtCl}_2(\text{NH}_3)_2$  in 0.1 M NaCl solution at  $\text{pH} = 7.4$ , suggest that the Rosenberg model for Pt(II) transport *in vivo* may need some modification. At physiological pH and chloride ion concentration, hydrolysis of the dichloro is measurable ( $t_{1/2} \sim 1$  h at  $37^\circ\text{C}$ ) and if no Pt(II) species are removed, an equilibrium di(chloro),

(chloro)(aqua), (chloro)(hydroxo) system is produced in about 6 h ( $37^\circ\text{C}$ ). There are now two neutral species [di(chloro) and (chloro)(hydroxo)] available for transport through the cell wall. If cell wall transfer is rapid relative to the hydrolysis rate, then the Rosenberg model is valid. However, if cell wall transfer is slow, then both the di(chloro) and (chloro)(hydroxo) would be available. It is also possible that the (chloro)(aqua) in the blood stream could be removed from the system via binding to plasma protein before cell wall transfer [via conversion to the (chloro)(hydroxo)] and this process would also upset the rapidly interconverting (chloro)(aqua)–(chloro)(hydroxo) equilibrium concentrations.

Within the cell, ( $[\text{Cl}^-] \sim 4$  mM), almost complete hydrolysis of the dichloro will occur ( $t_{1/2} \sim 2$  h at  $37^\circ\text{C}$ ) to give (at  $\text{pH} = 7.4$ ) a 50:50 (chloro)(aqua)–(chloro)(hydroxo) equilibrium mixture (assuming no Pt(II) loss). Pt(II) removal can occur, however via DNA binding to the (chloro)(aqua) [13]. Thus, while we are now beginning to understand the hydrolysis behaviour of  $\text{cis-PtCl}_2(\text{NH}_3)_2$  in aqueous solutions that model the physiological situation, we are still some way from a complete knowledge of the *in vivo* system.

## Acknowledgement

We thank the Universities Grants Committee for providing funds to purchase instruments used in this work.

## References

- 1 A. W. Prestayko, S. T. Crooke and S. K. Carter (eds.), *Cisplatin: Current Status and New Developments*, Academic Press, New York, 1980.
- 2 S. E. Miller and D. A. House, *Inorg. Chim. Acta*, **161** (1989) 131.
- 3 S. E. Miller and D. A. House, *Inorg. Chim. Acta*, **166** (1989) 189.
- 4 B. Rosenberg, *Biochimie*, **60** (1978) 859.
- 5 (a) C. P. Swainson, B. M. Colls and B. M. Fitzharris, *N. Z. Med. J.*, **98** (1985) 375.  
(b) R. F. Borch and M. Markman, *Pharmacol. Ther.*, **41** (1989) 371.
- 6 N. P. Johnson, J. D. Hoeschele and R. O. Rahn, *Chem.-Biol. Interact.*, **30** (1980) 151.
- 7 E. Segal and J.-B. Le Pecq, *Cancer Res.*, **45** (1985) 492.
- 8 S. Eapen, M. Green and I. M. Ismail, *J. Inorg. Biochem.*, **24** (1985) 233.
- 9 D. J. Evans, N. R. Ford and M. Green, *Inorg. Chim. Acta*, **125** (1986) L39.
- 10 D. J. Evans, M. Green and R. van Eldik, *Inorg. Chim. Acta*, **128** (1987) 27.
- 11 B. Van Hemelryck, J.-P. Girault, G. Chottard, P. Valadon, A. Laoui and J.-C. Chottard, *Inorg. Chem.*, **26** (1987) 787.
- 12 K. Inagaki, F. J. Dijt, E. L. M. Lempers and J. Reedijk, *Inorg. Chem.*, **27** (1988) 382.
- 13 A. Laoui, J. Kozelka and J.-C. Chottard, *Inorg. Chem.*, **27** (1988) 2751.
- 14 S. Murakami, K. Saito, A. Muromatsu, M. Moriyasu, A. Kato and Y. Hashimoto, *Inorg. Chim. Acta*, **152** (1988) 91.
- 15 R. N. Bose, R. D. Cornelius and R. E. Viola, *J. Am. Chem. Soc.*, **108** (1986) 4403.
- 16 N. Goswami, L. L. Bennett-Slavin and R. N. Bose, *J. Chem. Soc., Chem. Commun.*, (1989) 432.
- 17 D. Banerjee, F. Basolo and R. G. Pearson, *J. Am. Chem. Soc.*, **79** (1957) 4055.
- 18 J. W. Reishus and D. S. Martin, *J. Am. Chem. Soc.*, **83** (1961) 2457.
- 19 A. A. Grinberg and A. A. Korableva, *Russ. J. Inorg. Chem.*, **13** (1968) 565.
- 20 V. D. Panasyuk and N. F. Malashok, *Russ. J. Inorg. Chem.*, **13** (1968) 1405.
- 21 (a) J. E. Tegginis, K. W. Lee, J. M. Baker and E. D. Smith, *J. Coord. Chem.*, **1** (1971) 215; (b) K. W. Lee and D. S. Martin, *Inorg. Chim. Acta*, **17** (1976) 105.
- 22 J. R. Perumareddi and A. W. Adamson, *J. Phys. Chem.*, **72** (1978) 414.
- 23 A. A. Hincal, D. F. Long and A. J. Repta, *J. Parent. Drug Assoc.*, **33** (1979) 107.
- 24 R. F. Greene, D. C. Chatterji, P. K. Hiranaka and J. F. Gallelli, *Am. J. Hosp. Pharm.*, **36** (1979) 38.
- 25 A. I. Stetsenko and L. B. Sel'derkhanova, *Zh. Neorg. Khim.*, **26** (1981) 164.
- 26 C. M. Riley, L. A. Sternson, A. J. Repta and S. A. Slyter, *Polyhedron*, **1** (1982) 201.
- 27 C. M. Riley, L. A. Sternson, A. J. Repta and R. W. Siegler, *J. Chromatogr.*, **229** (1982) 373.
- 28 Y. Kitamura and K. Ida, *Inorg. Chim. Acta*, **88** (1984) 161.
- 29 R. N. Bose, R. E. Viola and R. D. Cornelius, *J. Am. Chem. Soc.*, **106** (1984) 3336.
- 30 J. L. Butour, A. M. Mazard and J. P. Macquet, *Biochem. Biophys. Res. Commun.*, **133** (1985) 347.
- 31 E. Segal and J.-B. Le Pecq, *Cancer Res.*, **45** (1985) 492.
- 32 R. N. Bose, R. D. Cornelius and R. E. Viola, *J. Am. Chem. Soc.*, **108** (1986) 4403.
- 33 P. C. Dedon and R. F. Borch, *Biochem. Pharmacol.*, **36** (1987) 1955.
- 34 A. A. Grinberg and A. A. Korableva, *Russ. J. Inorg. Chem.*, **13** (1968) 565.
- 35 D. D. Perrin and B. Dempsey, *Buffers for pH and Metal Ion Control*, Chapman and Hall, London, 1971.
- 36 R. W. Hay, L. J. Porter and P. J. Morris, *Aust. J. Chem.*, **19** (1966) 1197.
- 37 D. A. House, P. R. Normal and R. W. Hay, *Inorg. Chim. Acta*, **45** (1980) L117.
- 38 R. W. Hay and P. L. Cropp, *J. Chem. Soc., A*, (1969) 42.
- 39 A. J. Cunningham, D. A. House and H. K. J. Powell, *J. Inorg. Nucl. Chem.*, **33** (1971) 571.
- 40 A. A. El-Awady, *J. Chem. Soc., Dalton Trans.*, (1972) 1463.
- 41 J. McKenzie and D. A. House, *J. Inorg. Nucl. Chem.*, **39** (1977) 1843.
- 42 R. Faggiani, B. Lippert, C. J. L. Lock and B. Rosenberg, *J. Am. Chem. Soc.*, **99** (1977) 777.
- 43 B. Lippert, C. J. L. Lock, B. Rosenberg and M. Zvagulis, *Inorg. Chem.*, **17** (1978) 2971.
- 44 J. A. Broomhead, D. P. Fairlie and M. W. Whitehouse, *Chem.-Biol. Interact.*, **31** (1980) 113.
- 45 S. K. Aggarwal, J. A. Broomhead, D. P. Fairlie and M. W. Whitehouse, *Cancer Chemother. Pharmacol.*, **4** (1980) 249.
- 46 C. A. Bignozzi, C. Bartocci, C. Chiorboli and V. Carassiti, *Inorg. Chim. Acta*, **70** (1983) 87.
- 47 B. Rosenberg, *Cancer Treatment Rep.*, **63** (1979) 1433.
- 48 C. J. Boreham, J. A. Broomhead and D. P. Fairlie, *Aust. J. Chem.*, **34** (1981) 659.
- 49 T. G. Appleton, R. D. Berry, C. A. Davis, J. R. Hall and H. A. Kimlin, *Inorg. Chem.*, **23** (1984) 3514.
- 50 M. Chikuma and R. J. Pollock, *J. Magn., Reson.*, **47** (1982) 324.
- 51 T. G. Appleton, J. R. Hall, S. F. Ralph and C. S. M. Thompson, *Inorg. Chem.*, **28** (1989) 1989.
- 52 R. H. Earhart, *Cancer Treatment Rep.*, **62** (1978) 1105.
- 53 A. F. LeRoy, R. T. Lutz and R. L. Dedrick, *Cancer Treatment Rep.*, **63** (1979) 59.
- 54 I. A. G. Roos, *Chem. Austr.*, **47** (1980) 435.
- 55 S. J. Lippard, *ACS Symp. Ser., Inorg. Chem. Biol. Med.*, **140** (1980) 147.
- 56 J. P. Macquet, J. L. Butour and N. P. Johnston, *ACS Symp. Ser., Platinum, Gold, Other Met. Chemother. Agents: Chem. Biochem.*, **209** (1983) 75.
- 57 J. Reedijk, *Pure Appl. Chem.*, **59** (1987) 181.
- 58 P. Umaphathy, *Coord. Chem. Rev.*, **95** (1989) 129.